Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for ...

Eli LillyDemand for weight-loss drugs in India has shot up.And rivals Novo Nordisk and Eli Lilly are battling for market ...

Novo Nordisk (NVO) and Eli Lilly & Co. (NYSE:LLY), the global leaders in obesity medications, are now facing their first ...

Novo Nordisk, Eli Lilly Tea Up Next-Gen Drugs. For Novo Nordisk stock, though, it will be important to see how the company builds its pipeline of experimental weight-loss drugs, says Carnegie's Afzal.

Novo Nordisk and Eli Lilly are competing for the obesity-drug market, but their growth plans extend beyond weight-loss treatments. They face supply chain challenges, but both stocks show strong ...

Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are the top two healthcare stocks in the world based on market cap. Their diabetes and weight loss medications are a big reason these have been ...

Novo Nordisk and Eli Lilly reported booming sales Thursday from the new generation of diabetes and weight-loss drugs they’ve pioneered, as both drugmakers continue to scramble to keep up with ...

Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are the top two companies in the weight loss market right now. They are both raking in billions in revenue from their glucagon-like peptide-1 ...

Novo Nordisk and Eli Lilly are going to extraordinary lengths to secure the plants and machinery needed to churn out their popular appetite-suppressing drugs.

Eli Lilly hasn't grown earnings at nearly the same pace as Novo Nordisk, but expectations are extremely high. The stock currently trades for 45.7 times forward-looking earnings expectations.